Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation

Joanina K. Gicobi, Zhiming Mao, Grace DeFranco, Jacob B. Hirdler, Ying Li, Vianca V. Vianzon, Emilia R. Dellacecca, Michelle A. Hsu, Whitney Barham, Yiyi Yan, Aaron S. Mansfield, Yi Lin, Xiaosheng Wu, Taro Hitosugi, Dawn Owen, Michael P. Grams, Jacob J. Orme, Fabrice Lucien, Hu Zeng, Sean S. ParkHaidong Dong

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with advanced cancers who either do not experience initial response to or progress while on immune checkpoint inhibitors (ICIs) receive salvage radiotherapy to reduce tumor burden and tumor-related symptoms. Occasionally, some patients experience substantial global tumor regression with a rebound of cytotoxic CD8+ T cells. We have termed the rebound of cytotoxic CD8+ T cells in response to salvage therapy as T cell resilience and examined the underlying mechanisms of resilience. Resilient T cells are enriched for CX3CR1+ CD8+ T cells with low mitochondrial membrane potential, accumulate less reactive oxygen species (ROS), and express more malic enzyme 1 (ME1). ME1 overexpression enhanced the cytotoxicity and expansion of effector CD8+ T cells partially via the type I interferon pathway. ME1 also increased mitochondrial respiration while maintaining the redox state balance. ME1 increased the cytotoxicity of peripheral lymphocytes from patients with advanced cancers. Thus, preserved resilient T cells in patients rebound after salvage therapy and ME1 enhances their resiliency.

Original languageEnglish (US)
Article numbereadi2414
JournalScience Advances
Volume9
Issue number46
DOIs
StatePublished - Nov 2023

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation'. Together they form a unique fingerprint.

Cite this